Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 1/20 | 0.33 |
| ▸ | NQO2 | P16083 | 5/20 | 0.32 |
| ▸ | MAPT | P10636 | 2/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.31 |
| ▸ | S1PR1 | P21453 | 2/20 | 0.31 |
| ▸ | NPC1 | O15118 | 3/20 | 0.31 |
| ▸ | RAB9A | P51151 | 2/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | G6PD | P11413 | 1/20 | 0.31 |
| ▸ | PKM | P14618 | 1/20 | 0.31 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.30 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.30 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18538199 | 0.89 | NQO2 (0.39) | ESR1NQO2MAPTKDM4ES1PR1 | |
| SCHEMBL14280980 | 0.86 | CACNA1H (0.38) | ESR1CACNA1H | |
| SCHEMBL17445631 | 0.81 | MAPT (0.32) | ESR1MAPTCACNA1H | |
| SCHEMBL17269526 | 0.77 | CACNA1H (0.42) | ESR1KDM4EPOLBCACNA1H | |
| SCHEMBL17445640 | 0.77 | NQO2 (0.36) | NQO2MAPTS1PR1NPC1RAB9A | |
| SCHEMBL17445638 | 0.75 | CYP11B1 (0.31) | — | |
| SCHEMBL14666981 | 0.71 | PTPN11 (0.33) | MAPTKDM4ES1PR1POLB | |
| SCHEMBL14666983 | 0.71 | S1PR1 (0.36) | S1PR1 | |
| SCHEMBL14280981 | 0.70 | CACNA1H (0.38) | ESR1CACNA1H | |
| SCHEMBL10293004 | 0.70 | PGK1 (0.41) | KDM4ES1PR1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11678571-B2 | Organic electroluminescent device using aryl amine derivative containing heterocycle | IDEMITSU KOSAN CO., LTD. (JP) | 2023-06-13 | — | — | US | disclosed |
| US-9960360-B2 | Organic electroluminescent device using aryl amine derivative containing heterocycle | IDEMITSU KOSAN CO., LTD. (JP) | 2018-05-01 | — | — | US | disclosed |
| US-20180090685-A1 | ORGANIC ELECTROLUMINESCENT DEVICE USING ARYL AMINE DERIVATIVE CONTAINING HETEROCYCLE | IDEMITSU KOSAN CO., LTD. (JP) | 2018-03-29 | — | — | US | disclosed |
| US-20180040828-A1 | ORGANIC ELECTROLUMINESCENT DEVICE USING ARYL AMINE DERIVATIVE CONTAINING HETEROCYCLE | IDEMITSU KOSAN CO., LTD. (JP) | 2018-02-08 | — | — | US | disclosed |
| US-20160020403-A1 | ORGANIC ELECTROLUMINESCENT DEVICE USING ARYL AMINE DERIVATIVE CONTAINING HETEROCYCLE | IDEMITSU KOSAN CO., LTD. (JP) | 2016-01-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11678571-B2 | Organic electroluminescent device using aryl amine derivative containing heterocycle | RPS17, RPS19, CDK17 | ESR1 410/4885NQO2 1027/4885MAPT 3852/4885 |
| US-20180090685-A1 | ORGANIC ELECTROLUMINESCENT DEVICE USING ARYL AMINE DERIVATIVE CONTAINING HETEROCYCLE | SLC18A1, SLC18A2, AOC2 | ESR1 343/4885NQO2 1474/4885MAPT 2683/4885 |
| US-20180040828-A1 | ORGANIC ELECTROLUMINESCENT DEVICE USING ARYL AMINE DERIVATIVE CONTAINING HETEROCYCLE | SLC18A1, SLC18A2, AOC2 | ESR1 343/4885NQO2 1474/4885MAPT 2683/4885 |
| US-20160020403-A1 | ORGANIC ELECTROLUMINESCENT DEVICE USING ARYL AMINE DERIVATIVE CONTAINING HETEROCYCLE | SLC18A1, SLC18A2, AOC2 | ESR1 343/4885NQO2 1474/4885MAPT 2683/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.